Scientists from Scripps Research report that they have carried out a study on a number of neuroactive compounds which might yield clues to the design of future psychiatric and neurological drugs.

Please provide your email address to receive an email when new articles are posted on . Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing ...

A potential cornucopia of neuroactive compounds, which might yield clues to the design of future psychiatric and neurological drugs, has become more accessible to synthetic chemists. A potential ...

Women who go on to develop postpartum depression (PPD) may have characteristic levels of neuroactive steroids, molecules derived from the hormone progesterone, in their blood during the third ...

Usman “Oz” Azam, MD, CEO at Empyrean Neuroscience. Empyrean Neuroscience, Inc., a genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic ...

Cannabinoid Assets: multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. Including a proprietary molecule with significant ...

This article and associated images are based on a poster originally authored by Zhong Yu, Parker Ellingson, Denise Sullivan, Ben Streeter, Austin Passaro, Stacie Chvatal and Daniel Millard and ...

LA JOLLA, CA—A potential cornucopia of neuroactive compounds, which might yield clues to the design of future psychiatric and neurological drugs, has become more accessible to synthetic chemists, ...